Literature DB >> 9886504

Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome.

R Orvieto1, Z Ben-Rafael.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9886504     DOI： 10.1093/humrep/13.12.3306

Source DB:  PubMed          Journal:  Hum Reprod        ISSN： 0268-1161            Impact factor:   6.918


× No keyword cloud information.
  6 in total

1.  Prevention of ovarian hyperstimulation syndrome by early aspiration of small follicles in hyper-responsive patients with polycystic ovaries during assisted reproductive treatment cycles.

Authors:  Oluseye A Oyawoye; Bina Chander; Jocelyn Hunter; Ahmed Abdel Gadir
Journal:  MedGenMed       Date:  2005-08-16

2.  Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2015-08-21       Impact factor: 4.234

3.  A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome.

Authors:  S Ogawa; H Minakami; S Araki; T Ohno; M Motoyama; H Shibahara; I Sato
Journal:  J Assist Reprod Genet       Date:  2001-02       Impact factor: 3.412

4.  A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2015-11-04       Impact factor: 4.234

5.  HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.

Authors:  Jigal Haas; Alon Kedem; Ronit Machtinger; Shir Dar; Ariel Hourvitz; Gil Yerushalmi; Raoul Orvieto
Journal:  J Ovarian Res       Date:  2014-04-03       Impact factor: 4.234

6.  Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma.

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2013-11-05       Impact factor: 4.234
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.